AstraZeneca PLC
AZN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000901832
In the last 90 days, AstraZeneca PLC insiders filed 1 open-market purchase and 0 sales; 1,511 institutions reported holding it in 13F filings for Q2 2026, worth $151.3B in total; no superinvestor holds it.
13F holders, Q3 2026
Institutional positions in AstraZeneca PLC as of Sep 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
Q3 2026 data is still coming in (13F filing deadline: Nov 16, 2026), so these numbers are incomplete.
- Institutional holders
- 20
- +2 vs. Q2 2026
- Shares held
- 103.2K
- −11.0K (−9.7%) vs. Q2 2026
- Total value
- $16.7M
- −$4.96M (−22.9%) vs. Q2 2026
- New holders
- 3
- 3 more added
- Sold out
- 1
- 6 more reduced
1,493 institutions that held it in Q2 2026 haven't filed for Q3 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,511 | $151.3B |
| Q1 2026 | 1,388 | $148.4B |
| Q4 2025 | 1,410 | $46.4B |
| Q3 2025 | 1,292 | $37.9B |
| Q2 2025 | 1,223 | $34.7B |
| Q1 2025 | 1,251 | $37.0B |
| Q4 2024 | 1,222 | $33.7B |
| Q3 2024 | 1,230 | $39.1B |
| Q2 2024 | 1,213 | $39.0B |
| Q1 2024 | 1,141 | $33.8B |
| Q4 2023 | 1,131 | $33.2B |
| Q3 2023 | 1,075 | $33.7B |
| Q2 2023 | 1,093 | $35.4B |
| Q1 2023 | 1,057 | $35.0B |
| Q4 2022 | 1,063 | $34.2B |
| Q3 2022 | 968 | $28.3B |
| Q2 2022 | 1,019 | $34.9B |
| Q1 2022 | 984 | $34.3B |
| Q4 2021 | 952 | $29.4B |
| Q3 2021 | 911 | $31.1B |
| Q2 2021 | 772 | $26.1B |
| Q1 2021 | 757 | $20.4B |
Institutions, Q3 2026
Shares, value and share of portfolio for each institution holding AstraZeneca PLC; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Fortitude Family Office, LLC | – | – | – | – | Not filed |
| McGuire Capital Advisors Inc | – | – | – | – | Not filed |
| Trust Co | – | – | – | – | Not filed |
| Operose Advisors LLC | – | – | – | – | Not filed |
| Godfrey Financial Associates, Inc. | – | – | – | – | Not filed |
| Sunrise Financial Services, LLC | – | – | – | – | Not filed |
| Cordant, Inc. | – | – | – | – | Not filed |
| Golden State Equity Partners | – | – | – | – | Not filed |
| Darwin Advisors, LLC | – | – | – | – | Not filed |
| Financial Life Planners | – | – | – | – | Not filed |
| Lam Group, Inc. | – | – | – | – | Not filed |
| Prudential PLC | – | – | – | – | Not filed |
| FNY Investment Advisers, LLC | – | – | – | – | Not filed |
| Evelyn Partners Group Ltd | – | – | – | – | Not filed |